International Journal of Hematology-Oncology and Stem Cell Research最新文献

{"title":"Ocular Adnexal Lymphoma: Epidemiology and Clinical Characteristics","authors":"A. Sarici","doi":"10.4999/uhod.225970","DOIUrl":"https://doi.org/10.4999/uhod.225970","url":null,"abstract":"The aim of the study is to emphasize the frequency, clinical presentation, histopathologic features and TNM staging for each type of ocular adnexal lymphoma (OAL), and investigating treatment results and prognosis in our region. A retrospective review of 54 patients treated for primary and secondary OAL between Jan 2012 and Jan 2019 was made. Epidemiologic data, clinical characteristics of the tumor and recurrence free survival rates were evaluated. Patients with ocular adnexal lymphoma included 27 (50%) women and 27 (50%) men, with a mean age of 60.38±15.36 (range: 18-93) years at the time of presentation. Mean follow-up time was 40.88±20.75 (range 1-84) months. Histopathological diagnosis was extranodal marginal zone lymphoma in 75.9%, diffuse large B-cell lymphoma in 14.8%, chronic lymphocytic leukemia/small lymphocytic lymphoma in 5.6%, mantle cell lymphoma in 1.9% and follicular cell lymphoma in 1.9% of patients. Among 54 patients with OAL 66.7% had orbital, 22.2% had conjunctival, 5.6% had orbital plus conjunctival, 3.7% had orbital plus conjunctival and choroidal, 1.9% had conjunctival plus choroidal involvement. No recurrences were observed in 87.1% of patients during their follow-up. Our data indicates patient epidemiologic presentation of a single center.","PeriodicalId":38991,"journal":{"name":"International Journal of Hematology-Oncology and Stem Cell Research","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80749026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Calreticulin Mutations in Philadelphia Chromosome Negative Myeloproliferative Neoplasms","authors":"G. Gulbay","doi":"10.4999/uhod.225925","DOIUrl":"https://doi.org/10.4999/uhod.225925","url":null,"abstract":"","PeriodicalId":38991,"journal":{"name":"International Journal of Hematology-Oncology and Stem Cell Research","volume":"44 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87542813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effect of Metformin on SIK1 and SIK2 in MCF-7 Cell as an Anticancer Agent","authors":"Eser Çakmak","doi":"10.4999/uhod.226162","DOIUrl":"https://doi.org/10.4999/uhod.226162","url":null,"abstract":"Recent studies have shown that the use of metformin prevents the development and spread of cancer. Metformin may show this effect by increasing SIK1 and SIK2 gene expression. For this purpose, MCF-7 cells cultured in appropriate media were divided into 8 groups (1) control, (2) 10 ng/mL TGF- β 1, (3) 1.25 mM Metformin, (4) 2.5mM Metformin, (5) 20mM Metformin, (6) 1.25 mM Metform-in+10 ng/ml TGF- β 1, (7) 2.5mM Metformin+10 ng/ml TGF- β 1 and (8) 20mM Metformin+10 ng/ml TGF- β 1 doses were administered, respectively. PCR was performed for SIK1 and SIK2 genes, with GAPDH being the reference gene. Application of 10 ng/ml TGF- β 1 to MCF-7 cell significantly increased expression level of SIK1 mRNA by 1.6 fold. In non-invasive (TGF- β 1 not administered) MCF-7 cell, 2.5 mM and 20 mM metformin increased expression levels of SIK1 mRNA by 1.8, 3.4 fold and SIK2 mRNA by 1.6 and 3.3 fold respectively. In invasive (TGF- β 1 administered) MCF-7 cell, 1.25, 2.5 and 20 mM metformin increased expression levels of SIK1 mRNA by 3.5, 3.7, 4 fold; and SIK2 mRNA by 1.9, 2.4, 3.5 fold, respectively. Metformin increased SIK1 and SIK2 gene expression dose-dependently in non-invasive and invasive MCF-7 cells, more significantly in invasive ones. The increase in the SIK1 gene was greater than in SIK2. In the light of these results, investigating the effects of metformin on SIK1 and SIK2 genes in different TGF- β 1 sensitive cancer types may open new doors for cancer treatment.","PeriodicalId":38991,"journal":{"name":"International Journal of Hematology-Oncology and Stem Cell Research","volume":"15 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73515994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Patient with Monoclonal Gammopathy of Undetermined Significance and Detected Philadelphia Chromosome","authors":"T. Tran, Jennifer Cai, P. Ji, Xin Qing","doi":"10.14302/issn.2372-6601.jhor-22-4133","DOIUrl":"https://doi.org/10.14302/issn.2372-6601.jhor-22-4133","url":null,"abstract":"Background\u0000Monoclonal gammopathy of undetermined significance (MGUS) and chronic myeloid leukemia (CML) are diseases of different lineages. The diagnosis of both MGUS and CML in the same patient is a rare occurrence and has not been reported in much literature.\u0000\u0000Case Presentation\u0000We describe a 56-year-old man with a history of rheumatoid arthritis incidentally found to have an increase in IgA paraprotein. With less than 10% monoclonal plasma cells on the bone marrow biopsy and absence of hypercalcemia, renal failure, anemia and bone lesions, MGUS was diagnosed. The conventional cytogenetics at the time showed the presence of the Philadelphia chromosome in 30% of metaphases. However, there was no morphologic evidence of CML in the peripheral blood or bone marrow. Patient received no treatment and lost follow-up until 3 years later when a routine CBC showed leukocytosis and thrombocytosis. CML, chronic phase was diagnosed following a bone marrow aspiration and biopsy with Philadelphia chromosome observed in 100% of metaphases. Patient was treated with imatinib and later switched to dasatinib and complete molecular remission was continued to be achieved.\u0000\u0000Discussion and Conclusion\u0000Here we report a case of pre-leukemic CML as an incidental finding during the diagnosis of MGUS. The possible underlying mechanisms of the association are discussed although the exact cause of the coexistence is unclear.","PeriodicalId":38991,"journal":{"name":"International Journal of Hematology-Oncology and Stem Cell Research","volume":"557 2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77023043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between Perceived Stress and Neutropenia in Patients with Leukemia under Chemotherapy.","authors":"Mohsen Esfandbod,&nbsp;Maryam Abazaria Tehrani,&nbsp;Maryam Haghshomar,&nbsp;Pantea Arya,&nbsp;Bahareh Shateri Amiri,&nbsp;Gholamreza Toogeh,&nbsp;Manouchehr Keyhani","doi":"10.18502/ijhoscr.v16i2.9203","DOIUrl":"https://doi.org/10.18502/ijhoscr.v16i2.9203","url":null,"abstract":"<p><p><b>Background:</b> The most prominent part of the cellular response of the immune system is driven by neutrophils. These cells tend to decline following chemotherapy in patients with leukemia. Neutropenia is an influential factor in the prognosis of cancer patients. Stress reduces white blood cells (WBCs) and neutrophils are linked to an increased risk of infectious diseases after chemotherapy. We investigated the association between neutropenia and perceived stress following chemotherapy. <b>Materials and Methods:</b> We performed a cross-sectional study on 60 patients with leukemia in a university hospital. Participants completed self-report measures, including the demographic data and perceived stress scale (PSS) questionnaire. We compared rates of neutropenia, as a measure of chemotherapy prognosis, 10 days after chemotherapy in different stress levels. Moreover, the number of patients with polymorphonuclear (PMN) under 1000/microliter was compared at different stress levels.    <b>Results:</b> We found that neutropenia is directly correlated with negative stress perception and inversely correlated with positive stress perception. These effects appear more prominent in patients with PMN under 1000/microliter as the number of these patients was significantly more in groups with higher negative stress and less in groups with higher positive stress scores. <b>Conclusion:</b> It can be concluded that stress is correlated with neutropenia, and stress management in patients with leukemia will be accompanied by better recovery outcomes and reduced risk of infectious disease.</p>","PeriodicalId":38991,"journal":{"name":"International Journal of Hematology-Oncology and Stem Cell Research","volume":"16 2","pages":"103-109"},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/23/9e/IJHOSCR-16-103.PMC9547775.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40653275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SARS-CoV-2 Infection: A Possible Risk Factor for Incidence and Recurrence of Cancers.","authors":"Abdollah Jafarzadeh,&nbsp;Rohit Gosain,&nbsp;Seyed Mohammad Javad Mortazavi,&nbsp;Maryam Nemati,&nbsp;Sara Jafarzadeh,&nbsp;Abbas Ghaderi","doi":"10.18502/ijhoscr.v16i2.9205","DOIUrl":"https://doi.org/10.18502/ijhoscr.v16i2.9205","url":null,"abstract":"<p><p>COVID-19 and malignancy can affect the susceptibility of one another. Clinically recovered COVID-19 individuals display immune abnormalities that persist several months after discharge. The lymphopenia-related immunosuppression, functional exhaustion of cytotoxic lymphocytes (such as CD8⁺ cytotoxic T-cells and natural killer cells), hyperinflammatory responses, oxidative stress, downregulation of interferon response, development of the myeloid-derived suppressor cells, downregulation of tumor suppressor proteins and perhaps reactivation of the latent oncogenic viruses may directly and/or indirectly play a role in the cancer development and recurrence in severe COVID-19 patients. SARS-CoV-2-infected malignant patients may be at higher risk of death of their cancer than SARS-CoV-2-uninfected patients with the same cancers. On the other side, the patients with some types of cancers may be more vulnerable to SARS-CoV-2 infection compared with the non-cancerous individuals, due to their immunocompromised state resulted from malignancy, chemotherapy, and other concomitant abnormalities as well as perhaps greater expression of angiotensin-converting enzyme 2. SARS-CoV-2-infected cancerous patients are unable to produce an effective anti-virus immune response and may exhibit more severe forms of COVID-19. This review described the possible impacts of SARS-CoV-2 infection on cancer development and recurrence, and the potential cancer impacts on COVID-19 development, while the possible interventions are highlighted.</p>","PeriodicalId":38991,"journal":{"name":"International Journal of Hematology-Oncology and Stem Cell Research","volume":"16 2","pages":"117-127"},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c9/41/IJHOSCR-16-117.PMC9547773.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40653740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence and Prognostic Impact of WT-1 Gene Exon7 and 9 Mutations in Acute Promyelocytic Leukemia.","authors":"Fatemeh Nejatifar,&nbsp;Shahrbano Rostami,&nbsp;Barham Chahardouli,&nbsp;Amir Kasaeian,&nbsp;Mohammad Vaezi,&nbsp;Hossein Kamranzadeh,&nbsp;Seied Asadollah Mousavi,&nbsp;Abolfazl Farbod,&nbsp;Kamran Alimoghaddam,&nbsp;Ardeshir Ghavamzadeh","doi":"10.18502/ijhoscr.v16i2.9199","DOIUrl":"https://doi.org/10.18502/ijhoscr.v16i2.9199","url":null,"abstract":"<p><p><b>Background:</b> Wilms' tumor suppressor gene 1 (WT1) gene mutation has been reported to be a prognostic factor in normal-cytogenetic acute myeloid leukemia (AML) patients. Higher rates of mutation in the WT1 gene have been reported in several tumors including normal-cytogenetic AML patients. Data regarding WT1 mutations in acute promyelocytic leukemia (APL) is very scarce. In this study, we evaluated the incidence and impact of WT1 mutation on the outcome of APL patients. <b>Materials and Methods</b>: A total of 92 patients diagnosed with APL were studied in three distinct groups: early mortality, relapsed, and persistent complete remission. Genomic DNA of bone marrow samples of patients was analyzed. For quantification of expression levels of the WT1 gene, real-time quantitative PCR (rqPCR) was performed by a real-time PCR system. WT1 mutation and its impact on prognosis were considered the primary endpoint of the study. Statistical analysis was performed with STATA. <b>Results:</b> WT1 mutation frequency was 6.25% in the early mortality group (1/16 patients), 13.16% in the relapse group (5/38 patients), and 7.89% in the persistent complete remission group (3/38 patients). 8 mutations were in exon 7 and one mutation in exon 9. WT1 mutation in the relapse group was associated with a trend toward worse disease-free survival (DFS) while overall survival (OS) was not affected by WT1 mutation in univariate analysis. Patients with no mutations in WT1 and FLT3/ITD had better overall survival and disease-free survival compared to patients with mutations in the WT1 gene or FLT3/ITD in the relapse group. <b>Conclusion:</b> The frequency of WT1 gene mutations does not differ significantly between patients with early mortality, relapse, and persistent complete remission. The presence of WT1 mutation is associated with higher relapse and lower survival rates in relapse group patients.</p>","PeriodicalId":38991,"journal":{"name":"International Journal of Hematology-Oncology and Stem Cell Research","volume":"16 2","pages":"74-80"},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/66/f4/IJHOSCR-16-74.PMC9547776.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40653741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and Pathological Features of Double-Hit and Triple-Hit High-Grade B-Cell Lymphomas: A Retrospective Study from Three Portuguese Tertiary Centers.","authors":"Rui Almeida,&nbsp;Carlos Abrantes,&nbsp;Davide Gigliano,&nbsp;Rui Caetano Oliveira,&nbsp;Paulo Teixeira,&nbsp;Marta Viegas,&nbsp;Ângelo Rodrigues,&nbsp;Maria José Julião","doi":"10.18502/ijhoscr.v16i2.9202","DOIUrl":"https://doi.org/10.18502/ijhoscr.v16i2.9202","url":null,"abstract":"<p><p><b>Background:</b> High-grade B-cell lymphoma (HGBL) with rearrangements of <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6,</i> called double and triple-hit lymphomas (DTH-HGBL), are lymphoid malignancies with inferior outcomes when treated with standard chemotherapy. The identification of DTH-HGBL cases is challenging, considering their variable clinical, morphologic, and immunohistochemical features. <b>Materials and Methods</b>: Retrospective revision of medical data of patients diagnosed with DTH-HGBL confirmed by FISH, between January 2010 and January 2020, in three Tertiary Portuguese Hospitals (Coimbra Hospital and University Center, Portuguese Oncology Institute - Coimbra and Portuguese Oncology Institute - Porto). Pathological features, morphology, and immunohistochemical profile were evaluated by at least two experienced pathologists in hematopoietic and lymphoid neoplasms. <b>Results</b>: The cohort included 24 patients: 33.3% triple-hit, 58.3%, <i>MYC/BCL2</i> double-hit and 8.3% <i>MYC/BCL6</i> double-hit<i>.</i> There was no gender predominance, with a median age of 62.5±14.3y, 33.3% were diagnosed as nodal disease, and 66.7% as extranodal. Morphologic features of DLBCL were present in 50% of cases, morphological features of both DLBCL and Burkitt lymphoma (DLBCL/BL) in 45.8% and 4.2% of blastoid morphology. Immunohistochemical evaluation, regarding the Hans algorithm, revealed a Germinal center (GC)/GC-like subtype in 83.3% of cases and a non-GC/non-<i>GC</i>-like subtype in 16.7%.  MYC was positive in 42.9% and the median proliferative index was 80±12.4%. <b>Conclusion: </b>DTH-HGBL has a very broad range of features. We consider that a cost-effective approach would be to perform cytogenetic analysis in DLBCL and DLBCL/BL cases with GC/GC-like subtype. MYC and BCL2 immunohistochemistry can be useful to identify patients who may benefit from more aggressive therapies, but not as tools for case selection for FISH.</p>","PeriodicalId":38991,"journal":{"name":"International Journal of Hematology-Oncology and Stem Cell Research","volume":"16 2","pages":"94-102"},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/62/04/IJHOSCR-16-94.PMC9547779.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40653276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Unusual Case of Hemolytic Anemia Reversed with Liver Transplantation.","authors":"Vatsala Katiyar,&nbsp;Apaar Dadlani,&nbsp;Ishaan Vohra,&nbsp;Kamila Cisak,&nbsp;Ashutosh Barve","doi":"10.18502/ijhoscr.v16i2.9206","DOIUrl":"https://doi.org/10.18502/ijhoscr.v16i2.9206","url":null,"abstract":"<p><p>Spur cell anemia is acquired hemolytic anemia seen in patients with advanced liver disease, particularly in the setting of alcoholism, and warrants urgent liver transplant evaluation. We describe the case of a 58-year-old female with alcoholic cirrhosis who presented with worsening liver disease, profound anemia poorly responsive to blood transfusions, and multiple spur cells on the peripheral smear. She underwent a liver transplant, which led to the resolution of hematologic abnormalities and the need for transfusions. Our case highlights the significance of spur cell anemia as a harbinger of poor prognosis in patients with advanced liver disease and its reversibility with liver transplantation.</p>","PeriodicalId":38991,"journal":{"name":"International Journal of Hematology-Oncology and Stem Cell Research","volume":"16 2","pages":"128-130"},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/aa/8f/IJHOSCR-16-128.PMC9547772.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40653278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pediatric Cancer Registry at MAHAK Pediatric Cancer Treatment and Research Center: A Single-Center Study from Iran.","authors":"Mohammad Faranoush,&nbsp;Narjes Mehrvar,&nbsp;Yasaman Sadeghi,&nbsp;Maryam Tashvighi,&nbsp;Mardawig Alebouyeh,&nbsp;Azim Mehrvar","doi":"10.18502/ijhoscr.v16i2.9201","DOIUrl":"https://doi.org/10.18502/ijhoscr.v16i2.9201","url":null,"abstract":"Background: The childhood cancer registry in Iran is a hospital-based system and there is not any unique and national registry system for pediatric malignancies in Iran. According to the limitations and requirements, this study was designed to clarify the aspect of childhood malignancies in Iran and promote establishing the Iranian national childhood cancer registry system. Materials and Methods: This cross-sectional longitudinal study was implied on 1500 patients younger than 20-years old diagnosed with any malignancy and admitted at MAHAK Pediatric Cancer Treatment and Research Center (MPCTRC) from 2007 to 2014. Data collection was based on a validated questionnaire with three categories including demographic data, clinical data and type of malignancy, and outcomes. Collected data were analyzed using methods for qualitative and quantitative variables (P < 0.05) by SPSS software version 22. The survival rate was calculated by the Kaplan-Meyer method. Results: This study was implied on 1500 children with a mean age of 6.1 years old. The most common malignancy was acute leukemia (30.7%) followed by central nervous system tumors (27%). At the onset of starting treatment, the rate of conferring with relapse, metastasis, and secondary malignancies was 29%, 19.5%, and 1% respectively. In addition, 52 patients had bone marrow transplantation of whom, 14 cases died. Totally, 42% of patients died and the 3-years, 5-years, and 10-years overall survival rates were 67.7% ± 0.01, 60.3% ± 0.01, and 53.8% ± 0.01, respectively. Conclusion: Establishing a population-based pediatric cancer registry in Iran is necessary and will be useful for improving the survival rate of mentioned patients.","PeriodicalId":38991,"journal":{"name":"International Journal of Hematology-Oncology and Stem Cell Research","volume":"16 2","pages":"86-93"},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5c/a5/IJHOSCR-16-86.PMC9547774.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40653274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}